Welcome to our dedicated page for Takeda Pharm SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Takeda Pharmaceutical Company Limited American Depositary Shares (NYSE: TAK) on Stock Titan provides access to the company’s U.S. regulatory disclosures, primarily furnished on Form 20-F and Form 6-K as a foreign private issuer. Takeda prepares its consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) and uses these filings to report semi-annual and annual results, management guidance and material developments in its business.
Recent Form 6-K submissions include English translations of Takeda’s semi-annual securities report and earnings report (Kessan Tanshin) for the six-month period ended September 30, 2025. These documents present revenue by business area (Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, Neuroscience and Other) and by geographic region, along with operating profit, net profit, cash flow information and explanations of non-IFRS core measures such as core revenue, core operating profit and core EPS. They also discuss factors affecting performance, including generic erosion of specific products, foreign exchange impacts and changes in product mix.
Takeda’s 6-K filings additionally furnish press releases that describe key R&D and strategic events, such as Phase 3 data for zasocitinib (TAK-279) in plaque psoriasis, longer-term VERIFY and THRIVE results for rusfertide in polycythemia vera, portfolio decisions like discontinuation of cell therapy efforts, and revised forecasts for FY2025 revenue and profit. These exhibits provide context on how clinical outcomes, impairments of intangible assets and strategic partnerships influence Takeda’s financial outlook.
Through Stock Titan, users can review Takeda’s SEC filings as they are posted, while AI-powered tools can help summarize lengthy IFRS financial reports, highlight changes in management guidance, and surface important disclosures related to pipeline programs, impairments, capital allocation and regional performance. This makes it easier to understand how Takeda’s global biopharmaceutical operations and late-stage pipeline are reflected in its official U.S. regulatory documents.
Takeda Pharmaceutical Company Limited (TAK) has filed a Form 144 disclosing a proposed sale of 18,622 American Depositary Shares (ADSs) with an aggregate market value of $287,151.24. The shares—acquired through vested restricted stock units on 1 July 2025—represent less than 0.02% of the outstanding 123,490,548 ADSs. The transaction is slated for approximately 9 July 2025 on the NYSE and will be executed through Interactive Brokers LLC. No other insider sales have been reported in the past three months.
Takeda Pharmaceutical Company Limited (TAK) has filed a Form 144 indicating the proposed sale of 40,919 American Depositary Shares (ADSs) through Interactive Brokers on or about 07 July 2025. The aggregate market value of the planned sale is US$630,970.98, representing approximately 0.03 % of the company’s 123,490,548 ADSs outstanding. The shares derive from restricted stock unit (RSU) awards that vested on 01 July 2025 and are being sold for the account of an unnamed insider. No other sales have been reported by this person in the past three months, and the filer affirms there is no undisclosed material adverse information regarding the issuer.
The filing is procedural and signals an intent—not a completed transaction—allowing the insider to sell restricted or control securities under Rule 144. Given the limited size relative to Takeda’s float and market capitalization, the disclosure is generally viewed as immaterial to the company’s fundamental outlook.
Takeda Pharmaceutical Company Limited (TAK) has filed a Form 144 indicating an intended sale of 58,559 American Depositary Shares (ADSs), representing approximately 0.05 % of the company’s 123,490,548 ADSs outstanding. The proposed transaction is valued at US $902,979.78 based on the market price at the time of filing and is expected to take place on or about 07 / 09 / 2025 through NYSE, with Interactive Brokers LLC acting as broker.
The shares stem from restricted stock units that vested on 07 / 01 / 2025. The filer reports no sales of Takeda securities in the preceding three months. By signing the notice, the seller certifies the absence of undisclosed material adverse information about Takeda and affirms compliance with Rule 144 and, if applicable, any Rule 10b5-1 trading plan.
While the dollar amount is modest relative to Takeda’s market capitalization, Form 144 filings alert investors to potential insider activity that could influence near-term trading volume and sentiment.
The Form 144 filing indicates that an unidentified holder intends to sell 28,552 American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Ltd. (NYSE: TAK) through Interactive Brokers on or about 9 July 2025. The planned sale represents an aggregate market value of US$440,271.84, implying an approximate price of US$15.42 per ADS. The shares derive from restricted stock unit (RSU) awards that vested on 1 July 2025. No other securities have been sold by the filer in the past three months, and the total shares outstanding for Takeda are disclosed as 123,490,548 ADSs, making the proposed sale equal to roughly 0.02 % of the class. No adverse information about Takeda’s operations is asserted, and the filer affirms compliance with Rule 144 and Rule 10b5-1 representations.
Takeda Pharmaceutical Company Limited (TAK) – Form 144 filing discloses a planned insider sale of 26,874 American Depositary Shares (ADSs) with an aggregate market value of $414,397.08. The transaction will be executed through Interactive Brokers on the NYSE around 9 July 2025. The seller received the shares as part of restricted stock unit (RSU) awards that vested on 1 July 2025. No prior sales by this individual were reported in the past three months. Relative to the company’s 123.49 million ADSs outstanding, the proposed sale represents roughly 0.02% of shares, suggesting an immaterial dilution impact. The filer certifies no knowledge of undisclosed adverse information. While Form 144 notices can flag insider sentiment, the modest size and routine compensation-related nature of this sale indicate limited market significance.
Takeda Pharmaceutical Company Limited (TAK) has filed a Form 144 indicating a proposed sale of restricted securities.
- Securities to be sold: 4,477 American Depositary Shares (ADSs).
- Estimated market value: US $69,035.34.
- Broker: Interactive Brokers LLC, Greenwich, CT.
- Approximate sale date: 9 July 2025 on the NYSE.
- Shares outstanding: 123,490,548 ADSs – the planned sale represents less than 0.01% of this total.
- Source of shares: Vested Restricted Stock Unit (RSU) awards acquired 1 July 2025 as compensation from Takeda Pharmaceutical Company Limited.
- Prior sales: None reported in the past three months.
The filing is routine and does not include earnings data or announce any strategic transactions. It simply registers a modest insider sale that is immaterial relative to the company’s share base.
Takeda Pharmaceutical Company Limited (NYSE: TAK) has filed a Form 144 indicating a proposed insider sale of American Depositary Shares (ADSs) under Rule 144.
- Securities to be sold: 34,857 ADSs.
- Estimated market value: US$537,494.94.
- Broker: Interactive Brokers LLC, Greenwich, CT.
- Approximate sale date: 09 July 2025.
- Shares outstanding: 123,490,548 ADSs – the planned sale represents roughly 0.028% of the float.
- Source of shares: Vested Restricted Stock Unit awards acquired 01 July 2025 as compensation.
No other securities have been sold by the filer in the past three months and the filer affirms the absence of undisclosed adverse information. As this notice covers a relatively small position and involves previously issued shares, it does not affect Takeda’s share count or capital structure. Investors typically view Form 144 filings as neutral-to-slightly-negative sentiment indicators because they reflect potential insider selling, but the immaterial size here limits market impact.
Takeda Pharmaceutical Company Limited (NYSE: TAK) filed a Form 144 indicating the proposed sale of 169,313 American Depositary Shares (ADSs). The securities were acquired via restricted stock unit (RSU) awards that vested on 07/01/2025 and have an aggregate market value of US$2,610,806.46. The filer plans to sell the shares through Interactive Brokers LLC on or about 07/09/2025. According to the notice, the issuer has 123,490,548 ADSs outstanding, and the planned sale will be executed on the NYSE.
Form 144 is a disclosure of intent, not a confirmation that the sale has occurred. The filing contains no indication of undisclosed adverse information, and no other sales by the filer were reported in the past three months. No financial performance metrics or strategic updates were provided; the document is strictly related to the planned disposition of shares.
This Form 144 filing indicates that an unidentified holder of Takeda Pharmaceutical Company Limited (TAK) American Depositary Shares (ADSs) plans to sell up to 5,608 ADSs through Interactive Brokers on or about 9 July 2025 on the NYSE. The block is valued at roughly $86,475 based on the market price reported in the form. The shares derive from restricted-stock-unit awards that vested on 1 July 2025. With 123.49 million ADSs outstanding, the proposed sale represents only about 0.0045 % of the float, implying immaterial dilution or trading-volume impact. No other sales have been made by the filer in the past three months, and the signer certifies the absence of undisclosed adverse information. While insider sales occasionally raise sentiment concerns, the size and routine compensation origin suggest limited market significance.